Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ian R. Hardy"'
Autor:
Scott M. Wemlinger, Chelsea R. Parker Harp, Bo Yu, Ian R. Hardy, Matthew Seefeldt, Jennifer Matsuda, Michael Mingueneau, Kerri A. Spilker, Thomas O. Cameron, James W. Larrick, Andrew Getahun, John C. Cambier
Publikováno v:
J Immunol
The BCR comprises a membrane-bound Ig that is noncovalently associated with a heterodimer of CD79A and CD79B. While the BCR Ig component functions to sense extracellular Ag, CD79 subunits contain cytoplasmic ITAMs that mediate intracellular propagati
Publikováno v:
Immunotherapy. 12:89-103
Recently, two chimeric antigen receptor (CAR) T cell therapies were approved based on their remarkable efficacy in patients with hematological malignancies. By contrast, CAR-T cell therapies results in solid tumors have been less promising. To develo
Autor:
Elvira Khialeeva, Lance Sherwood, Ian R. Hardy, Jennifer Ma, Meredith Weglarz, Christopher J. Ackerman, Sung Chang Lee, Sophie Viaud, Brent Benish, Travis S. Young, Eric N. Hampton, Ashley K. Woods, Vanessa Núñez
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Chimeric antigen receptor (CAR) T cell therapy represents a powerful strategy in immuno-oncology. Nevertheless, associated life-threatening toxicities and chronic B cell aplasia have underscored the need to control engineered T cells in
Autor:
Vanessa Núñez, Oded Singer, Ashley K. Woods, Chan Hyuk Kim, David T. Rodgers, Ian R. Hardy, Feng Wang, Peter G. Schultz, Andrew D Schulman, Jennifer S. Y. Ma, Jiayin Shen, Travis S. Young, Eric Hampton, Yu Cao, Nitya S. Ramadoss, Magdalena Mazagova, Juanjuan Du, Timothy M. Wright
Publikováno v:
Proceedings of the National Academy of Sciences. 113
Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical trials for B-cell malignancies. However, safety concerns related to the inability to control CAR-T cells once infused into the patient remain a significant c
Autor:
Nicole A. Hertzberg, Walter Ferlin, Pauline Malinge, Nadia Anceriz, Mia J. Smith, Laura Cons, Walter Reith, Matthew B. Seefeldt, Ian R. Hardy, Giovanni Magistrelli, Vanessa Buatois, Magali Irla, Guillemette Pontini, François Rousseau, John C. Cambier, Eric Hatterer, Ashley A. Fletcher, Laurence Chatel, Andrew Getahun, Marie Kosco-Vilbois
Publikováno v:
Journal of Immunology, Vol. 192, No 4 (2014) pp. 1641-50
B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell–targeted therapies in